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RESEARCH
Health-related quality of life after deep 
vein thrombosis
Kristin Kornelia Utne1,2,7* , Mazdak Tavoly1,2,3, Hilde Skuterud Wik4, Lars Petter Jelsness‑Jørgensen1,5, 
René Holst1,6, Per Morten Sandset2,4 and Waleed Ghanima1,2
Abstract 
Background: Health‑related quality of life (HRQoL) is known to be impaired in patients who develop post‑throm‑
botic syndrome (PTS) following deep vein thrombosis (DVT). However, there is limited knowledge of the long‑term 
HRQoL after DVT compared to controls without DVT. The objectives of this study were to evaluate long‑term HRQoL 
following DVT and to compare that with age and sex matched control group and to population norms as well as to 
investigate possible predictors for reduced HRQoL.
Methods: HRQoL was evaluated in 254 patients with confirmed DVT using the generic EQ‑5D and the diseases spe‑
cific VEINES‑QOL/Sym questionnaire, whereas PTS was assessed by the Villalta scale. Patients were asked to give the 
EQ‑5D questionnaire to two friends of same age‑ (±5 years) and sex (buddy controls).
Results: Patients scored significantly lower on all dimensions of EQ‑5D compared to controls. EQ‑5D index value 
was lower in patients compared with buddy controls; mean 0.79 (SD 0.17; IQR 0.72–1.00) versus 0.9 (SD 0.12; IQR 
0.80–1.00), p < 0.001. EQ‑5D index value was also significantly lower than age‑ and sex‑adjusted population norms 
(p < 0.001). PTS and obesity (BMI >30/m2) were significantly associated with impaired HRQoL assessed by EQ‑5D 
index value (odds ratio [OR] 11.0: 95 % confidence interval [CI] 4.6–29.7; and 2.3: 95 % CI 1.1–4.8, respectively) and 
VEINES‑QOL (OR 28.2: 95 % CI 10.6–75.0; and OR 4.1: 95 % CI 1.7–9.7, respectively).
Conclusion: Long‑term HRQoL was significantly impaired in DVT patients compared with buddy controls and popu‑
lation norms. PTS and obesity were independently associated with impaired HRQoL.
Keywords: Controls, Deep vein thrombosis, EQ‑5D‑3L, HRQoL, Population norms, VEINES‑QOL/Sym
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Strengths and limitations of this study
Strengths
  • Unselected DVT patients.
  • Age- and sex-matched population norms and a con-
trol group were used for comparison with patients.
  • Two validated measures for health-related quality 
of life (HRQoL) were used as the outcome, one for 
generic and one for disease specific HRQoL.
Limitations
  • Patients were identified retrospectively.
  • Incomplete response of buddy controls and coverage 
with the disease specific questionnaire.
  • Patients were seen at a single time-point.
Background
Deep vein thrombosis (DVT) is a common medical 
emergency estimated to affect about 460,000 people in 
the European Union countries each year (Cohen et  al. 
2007). Basic treatment of DVT comprises use of anti-
coagulants to block the activation of coagulation and to 
prevent thrombus extension (Kearon et al. 2012). Despite 
adequate anticoagulation, symptoms of DVT may take 
months to subside, and many patients develop long-term 
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sequel. Generally, short- and long-term outcomes of 
DVT can be divided into those related to the treatment, 
such as bleeding, and those related to direct or indirect 
effects of the thrombus, such as pulmonary embolism, 
post-thrombotic syndrome (PTS) and recurrent venous 
thrombosis (Prandoni et  al. 1996). PTS is a syndrome 
that affects up to 50 % of patients after DVT and is char-
acterized by varying grades of pain, heaviness, swelling, 
and at worst, chronic ulceration of the leg (Ashrani and 
Heit 2009). PTS have been shown to negatively impact 
health-related quality of life (HRQoL) after a DVT (Kahn 
et al. 2014; Baldwin et al. 2013).
HRQoL assessed by patient-reported outcome meas-
ures (PROMs), typically obtained by questionnaires, 
provide essential information regarding the impact of 
diseases and treatments on patients’ physical-, psycho-
logical-, and social-functioning (Paller and Smith 2014). 
Comprehensive assessment of HRQoL should include the 
use of both generic and disease-specific measures (Lamp-
ing et al. 2003).
Although many studies have been published on 
HRQoL after DVT, most of these studies have focused 
on the impact of PTS on HRQoL (Ghanima et al. 2011; 
Kahn et al.  2005; Catarinella et al. 2014), whereas little 
is known on the long-term impact of DVT on HRQoL as 
compared to the general population. The primary aim of 
this study was thus to evaluate long-term HRQoL follow-
ing DVT compared to population norms and age- and 
sex-matched controls as well as to investigate possible 
predictors of impaired HRQoL in these patients.
Materials and methods
Patient population
Patients that were diagnosed and treated for DVT at the 
Østfold Hospital, Norway, between 2004 and 2014 were 
identified from Østfold Hospitals Thrombosis Registry and 
by searching hospital databases for ICD-10 codes of DVT 
(I80.1, I80.2 and I80.3). We identified 721 patients with 
an objectively confirmed diagnosis of DVT (by compres-
sion ultrasonography), of whom 137 were deceased and 94 
patients were excluded prior to invitation for reasons pre-
sented in Fig. 1. In total 490 patients were invited to partici-
pate. The inclusion period ran from 2012 to 2014. As shown 
in Fig. 1, 72 invited patients declined to participate, 59 were 
not able to show up for examination, 94 did not respond to 
the invitation, and 11 died during assessment period. Thus, 
the final study population comprised 254 patients.
Methods
Clinical and epidemiological data
This population-based, cross-sectional study was 
designed to evaluate HRQoL among patients who 
had sustained one or more DVTs during the previous 
1–10 years. Patients met at the hospital for a clinical eval-
uation including assessment of PTS by the Villalta scale. 
Information on localization of DVT, recurrent DVT(s), 
comorbidities, body mass index (BMI), sociodemo-
graphic data, presence of provoking factor, use of elastic 
compression stockings (ECS), and type and duration of 
anticoagulant treatment were acquired from the patients 
during the interviews or from the medical records.
Assessment of PTS
PTS was diagnosed in the index leg by the Villalta score 
(Kahn et  al. 2009). This score includes the five patient-
rated symptoms: pain, cramps, heaviness, paraesthesia, 
and pruritus; and the six clinician-rated signs: edema, 
skin induration, hyperpigmentation, pain during calf 
compression, venous ectasia, and redness. Each sign or 
symptom is rated as 0 (none), 1 (mild), 2 (moderate) or 
3 (severe), and summed to produce a total score. Severity 
of PTS is divided into the following 4 groups depending 
on score; 0–4 points indicates no PTS, 5–9 points indi-
cates mild-, 10–14 points indicates moderate-, and  >14 
points indicates severe PTS.
Health‑related quality of life (HRQoL)
HRQoL was assessed using two questionnaires; EQ-5D 
and VEINES-QOL/Sym. Patients were sent the question-
naires by mail and were asked to bring back completed 
forms to the scheduled visit.
EQ-5D is a standardized and widely used instrument 
to assess generic HRQoL (EuroQol 1990; Brooks 1996). 
It is a descriptive system of HRQoL states consisting of 
five dimensions (mobility, self-care, usual activities, pain/
discomfort, anxiety/depression), each of which can be 
scored according to three levels of severity (no problems/
moderate problems/extreme problems). EQ-5D health 
states, defined by the EQ-5D descriptive system, may be 
summarized as a weighted mean of the five dimensions 
(Sorensen et al. 2009; Kim et al. 2008). The EQ-5D index 
value scores assigns each health state a value ranging 
from −0.59 to 1.00 where 1.00 indicates perfect health, 
0.00 indicates death and negative scores indicates health 
worse than death. The questionnaire contains in addition 
the EQ Visual Analogue Scale (EQ VAS), which is scored 
from 0 to 100—from the “worst imaginable health state” 
to the “best imaginable health state”.
VEINES-QOL/Sym is a disease specific HRQoL 
instrument for use in chronic venous diseases of the 
leg (CVDL). The questionnaire consists of 26 items. It 
includes questions about symptoms due to CVDL (ten 
items), limitations in daily activities due to CVDL (nine 
items) and psychological impact (five items), as well 
as questions asking about the amount of change in the 
respondent’s leg problem over a 1-year period (one item) 
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and the time of day that the leg problem is most intense 
(one item). Responses are rated on 2-point to 7-point 
descriptive scales, and two summary scores are computed, 
VEINES-QOL and VEINES-Sym. These scores were com-
puted using standard scoring algorithms obtained from 
the authors (Lamping et  al. 2003). 195 (77  %) patients 
returned a complete VEINES questionnaire.
Population norms and controls
HRQoL among the DVT patients was compared to the 
general Danish population by comparing the EQ-5D 
index value in the study sample with age- and sex-
adjusted Danish population norms. Weighted time-
trade-off (TTO) values were calculated by multiplying 
the number of patients per defined age group with the 
age-appropriate EQ-5D index value, established by 
Sorensen et al. (Sorensen et al. 2009) in 2009. Mean value 
in each gender group was then calculated (Table 3). Dan-
ish population norms were chosen due to lack of Norwe-
gian population norms for EQ-5D.
Using the population norm data as reference, we could 
not ascertain the absence of patients with a history of 
DVT in this control group. In order to do so, we included 
a second control group that was acquired by asking 
our study subjects to hand over an EQ-5D form to two 
friends or relatives without a history of venous thrombo-
sis with the same age- (±5 years) and sex. These buddy 
controls were asked to answer the questionnaire, how-
ever, only 122 controls responded and returned HRQoL 
questionnaires.
HRQoL assessed by VEINES-QOL/Sym was not 
compared between patients and buddy-controls, as 
VEINES-QOL/Sym is disease specific questionnaire 
designed for patients with DVT.
Assessment of clinical significance
For evaluation of whether a statistical difference between 
patients and control groups actually represented a clini-
cally significant difference we used a minimally impor-
tant difference (MID) in EQ-5D index value of 0.074, 
based on recommendations in the literature (Walters and 
Brazier 2005). For EQ VAS the MID is not known and 
was defined as half the SD among the controls, based on 
recommendations in the literature (Pickard et al. 2007).
Predictors of HRQoL
We tested for the following possible predictors of 
reduced HRQoL based on clinical experience and infor-
mation available in the literature (Kahn et al. 2004, 2007, 
2008): age, sex, employment status, comorbidities (active 
or previous cancer, chronic obstructive pulmonary dis-
ease (COPD), heart failure, and), obesity, smoking, pro-
voked or unprovoked DVT, recurrent DVT, localization 
of DVT, ongoing anticoagulation, obesity, PTS, and use 
of ECS.
Index DVT was defined as the first thrombosis 
recorded in the hospital thrombosis registry. Proximal 
thrombosis was defined as a DVT in the popliteal vein or 
proximal, while DVT below the popliteal vein was con-
sidered distal. DVT was considered provoked if throm-
bosis was triggered by one of the following risk factors: 
orthopedic surgery, other extensive surgery, trauma or 
hospitalization with immobilization  >3  days ≤12  weeks 
prior to index event, pregnancy or birth ≤12 weeks prior 
N=490 - Invited N=231 - Excluded
Died during assessment period - N=11
N=254 - Final study population
N=721 - Assessed for eligibility
Not able to show up - N=59
Non-responders - N=94
Declined to participate - N=72
N=137 - Dead
N=16 - Geographically unavailable
N=76 - Deemed incapable of complying
N=2 - Wrong diagnosis registered
Fig. 1 Flow‑chart of patient sample
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to index event, or long haul flight for over 4 h ≤12 weeks 
prior to index event. (Hansson et  al. 2000). Recurrent 
DVT was registered when patient had sustained more 
than one DVT, before or after index event. Employment 
was categorized into either employed (all patients work-
ing or studying) or unemployed (all patients not attend-
ing any form of work).
Statistical analysis
Categorical variables were expressed as frequencies and 
proportions, while continuous variables were expressed 
by as mean and standard deviation (SD) when normally 
distributed and by median and interquartile range (IQR) 
when distribution was skewed. When comparing con-
tinuous variables deviating from the normal distribution 
between groups, non-parametric test (Mann–Whitney) 
was used. When comparing the EQ-5D index values 
between patients and controls, the results were presented 
as mean and standard deviation (SD), in addition to IQR, 
although the data deviate from normal distribution, 
since this is considered the standard method for report-
ing EQ-5D (Enden et al. 2007; Kwon and Kim 2016). All 
scores were consequently dichotomized into impaired/
not impaired HRQoL. Impaired HRQoL was defined as 
scores <the 25th percentile among patients.
In the EQ-5D dimensions, the outcome “extreme prob-
lems” occurred very rarely, and this level was merged 
with the level “some problems” for the statistical analyses. 
Chi square test was used for comparison of the EQ-5D 
dimensions between patients and buddy-controls.
We performed univariate analysis using simple logis-
tic regression to find possible predictors for impaired 
HRQoL. All variables, which were significantly associated 
with impaired HRQoL, were included in the multivariate 
models and backward variable selection was used. Wald 
test was used for assessment of significance in the logis-
tic regression analyses. The issue of multiple testing was 
handled by a Bonferroni correction. A significance level 
of 2.5 % was therefore used for all tests, giving a joint sig-
nificance level of 5 % (alpha 2.5 %).
Statistical analyses were performed using the Statistical 
Package for Social Science version 21.0 (SPSS Inc., Chi-
cago, IL, USA).
Results
The patients’ characteristics are summarized in Table 1. 
Mean age of the 254 patients at inclusion was 60 (SD 
13) years and 167 (66 %) were males. Mean observation 
time from diagnosis of DVT (index event) to study inclu-
sion was 5 (SD 2) years. Seventy-nine patients (31 %) had 
experienced more than one DVT; 36 (14 %) patients had 
DVT before and 43 (17 %) after the index DVT (Table 1). 
Forty-six patients (19 %) had ipsi-lateral recurrent DVT, 
before or after index DVT. One hundred and twenty-one 
patients (48  %) were diagnosed with PTS; but only 12 
(5 %) with severe affliction (Table 1).
Mean age of the patients (n  =  100) having a buddy 
control was 63 (SD 12) years at inclusion and 68 (68 %) 
were male. Mean observation time from DVT to study 
inclusion in this group was 4 (SD 2, range 1–10) years; 22 
(22 %) had ipsi-lateral recurrent DVT.
The mean age of patients who completed the VEINES 
questionnaire (n = 195) was 61 (SD 13) at inclusion and 
128 (66  %) were males. Mean observation time from 
Table 1 Socio-demographic and  clinical characteristics 
of the study sample at the time of inclusion in the study
COPD chronic obstructive pulmonary disease, ECS elastic compression stockings, 
PTS post thrombotic syndrome, Obesity body mass index >30, SD standard 
deviation
a The exact location of DVT was missing in 6 patients as these patients were 
diagnosed at another institution and were referred to Ostfold hospital for follow 
up
b 72 patients (28 %) were diagnosed mild-, 37 (15 %) with moderate-, and 12 
(5 %) with severe PTS
Variable Study sample (n = 254)
N (%)
Demographics
Male 167 (66)
Age, mean (SD) 60 (13)
Unemployed 135 (53)
Years since diagnosis, mean (SD) 5 (2)
Time on anticoagulation (months), 
median (IQR)
6 (3–34)
Index DVT in left leg 132 (52)
Proximal DVTa 161 (64)
Recurrent DVT 79 (31)
Still on anticoagulation therapy 74 (29)
Any use of ECS after DVT 233 (93)
PTSb 121 (48)
Comorbidities
Current smoker or previous smoker 131 (53)
Current or previous cancer 20 (8)
Heart failure 12 (5)
COPD 13 (5)
Obesity 76 (30)
Provoking factors
Orthopedic surgery 25 (10)
Other extensive surgery 8 (3)
Trauma which caused immobilization 46 (18)
Pregnancy or birth 12 (5)
Hospitalization with immobilization 3 (1)
Long haul flight 25 (10)
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diagnosis of DVT to study inclusion was 5 (SD 2, range 
1–9); 35 (18 %) had ipsi-lateral recurrent DVT.
HRQoL
Patients scored significantly lower than controls on all 
EQ-5D dimensions (Table 2). More than 60 % of patients 
complained about pain/discomfort, which was the most 
prevalent complaint as compared to 31  % of the buddy 
controls. Anxiety and depression was present in 29 % of 
patients as compared to 12 % in the buddy control group. 
Mean EQ-5D index value (0.79; SD 0.20; IQR 0.72–1.00) 
in patients was significantly lower than in buddy controls 
(0.91; SD 0.12; IQR 0.80–1.00), (p < 0.001). The difference 
of 0.12 was larger than 0.074, which was larger than the 
defined MID.
The mean score for EQ VAS (72; SD 19) was signifi-
cantly lower in patients compared to buddy controls (82; 
SD 15), (p  <  0.001) (Table  2). The difference of 10 was 
larger than 0.5 SD in patient group, which was consid-
ered as MID.
The mean EQ-5D index values for females (0.76; SD 
0.19; IQR 0.70–0.82) and males (0.80; SD 0.21; IQR 
0.76–1.00) were significantly lower than the correspond-
ing age-adjusted Danish population norms for females 
(0.84) and males (0.88) (p < 0.001 for both comparisons). 
For both genders the difference was 0.8 which was larger 
than the defined MID (Table 3).
The mean score of VEINES-QOL was 47.8 (SD 10.5). 
The largest difference in VEINES scores was found when 
comparing patients with and without PTS. Mean score of 
patients with PTS was 40.6 (SD 10.29) compared to 54.2 
(SD 5.5) in PTS free patients, p < 0.001. Obese patients 
had a mean score of 41.9 (SD 10.9) compared to 50.2 (SD 
9.4), p  <  0.001. Females scored significantly lower than 
males [45.2 (SD 11.4) and 49.3 (SD 9.8), p = 0.01]. Dis-
tal versus proximal location of DVT did not significantly 
influence VEINES-QOL, p =  0.5; neither did recurrent 
versus first time DVT, p = 0.2. Results for VEINES Sym 
were approximately the same as for VEINES-QOL (not 
shown).
Table 2 EQ-5D-3L among patients and controls
PTS post-thrombotic syndrome, SD standard deviation
a Man Whitney U test
b In the EQ-5D questionnaire, the outcome ‘extreme problems’ occurred very rarely, and this level was merged with the level ‘some problems’ for the statistical 
analyses
c Chi square test for independence
Patients (n = 254) Controls (n = 122) Pa (patients versus controls)
Mean (SD) Mean (SD)
EQ‑5D index value 0.79 (0.20) 0.91 (0.12) <0.001
EQ VAS 72 (19) 82 (15) <0.001
EQ-5D dimension Patients with problemsb Controls with problemsb Pc
n (%)  n (%)
Mobility 79 (31) 13 (11) <0.001
Self‑care 17 (7) 0 (0) 0.003
Usual activities 68 (27) 8 (7) <0.001
Pain/discomfort 157 (62) 38 (31) <0.001
Anxiety/depression 74 (29) 15 (12) <0.001
Table 3 Weighted time to trade of (TTO) values for EQ-5D index value
Weighted TTO values were calculated by number of patients per age group multiplied by age appropriate EQ-5D index value, mean value in each gender group was 
calculated. TTO values to compare mean study sample values with: male 0.88, female 0.84
Age group <29 30–39 40–49 50–59 60–69 70–79 >80
Male n = 167
No of patients 1 2 18 52 59 21 14
Index value in Danish population 0.94 0.93 0.91 0.89 0.88 0.85 0.80
Female n = 87
No of patients 6 8 8 15 25 15 10
Index value in Danish population 0.92 0.90 0.88 0.86 0.84 0.82 0.72
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Predictors of impaired HRQoL
The cut-off for impaired HRQoL was 0.72 and 60 for 
EQ-5D index value and EQ-VAS, respectively. Obesity, 
PTS, and unemployment, were found to be associated 
with impaired EQ-5D index and EQ VAS scores in simple 
logistic regression analyses (Table 4).
In the multiple logistic regression models of EQ-5D 
index values and EQ VAS, PTS and obesity remained sig-
nificantly associated with impaired HRQoL, while unem-
ployment remained significant as measured by EQ VAS 
alone (Table 4).
The cut-off for impaired HRQoL was 41.7 and 40.9 for 
VEINES-QOL and VEINES Sym, respectively. In the sim-
ple analysis female gender, obesity, and PTS were found 
to be associated with impaired VEINES-QOL (Table 5), 
whereas only PTS and obesity were associated with 
impaired VEINES-Sym.
In the multiple logistic regression analysis, only PTS 
and obesity were found as independent predictors of 
reduced QoL assessed by VEINES-QOL (Table  5) and 
VEINES Sym (not shown).
Discussion
In this population-based cross-sectional study HRQoL 
was assessed by EQ-5D and VEINES-QOL/Sym. HRQoL 
assessed by EQ-5D was impaired among DVT patients 
compared to population norms and buddy controls. To 
our knowledge, no other studies have compared long-term 
HRQoL in an unselected DVT population to age- and sex-
matched controls or population norms using EQ-5D.
Table 4 Crude- and adjusted odds ratios (OR) for impaired HRQoL assessed by EQ-5D index value and EQ-VAS
DVT deep vein thrombosis, ECS elastic compression stockings, BMI body mass index, PTS post thrombotic syndrome, COPD chronic pulmonary obstructive disease, 
Impaired HRQoL EQ-5D index value <25th percentile in patient group (0.72) and EQ VAS value <25th percentile in patient group (60)
# Wald test
a Adjusted for all other significant variables in the multivariate model
b In or above popliteal vein
Variable EQ-5D index value EQ-VAS
N = 254 Crude OR 
(95 % CI)
p value# Adjusted ORa 
(95 % CI)
p value# 
adjusted
N = 250 Crude OR 
(95 % CI)
p value# Adjusted 
ORa (95 % 
CI)
p value# 
adjusted
Female 87 2.7 (1.3–5.3) 0.05 86 1.3 (0.6–2.8) 0.5
Age (continu‑
ous variable)
254 1.0 (1.0–1.0) 0.4 250 1.0 (1.0–1.1) 0.03 1.0 (1.0–1.0) 0.5
Time from 
diagnosis to 
examination 
(continuous 
variable)
254 1.1 (1.0–1.3) 0.2 250 1.0 (0.8–1.1) 0.7
Unemployed 135 2.5 (1.3–4.9) 0.006 2.3 (1.1–4.8) 0.03 135 4.2 (2.1–8.4) <0.001 4.3 (2.0–9.0) <0.001
BMI > 30.0 kg/
m2
76 3.1 (1.7–5.7) <0.001 2.3 (1.1–4.2) 0.005 75 3.3 (1.8–6.1) 0.003 2.5 (1.3–5.0) 0.008
Current or pre‑
vious daily 
smoking
131 1.2 (0.7–2.2) 0.5 127 1.2 (0.7–2.2)
Still on antico‑
agulation
74 0.8 (0.4–1.5) 0.4 72 1.2 (0.6–2.3) 0.6
No ECS after 
DVT
21 1.1 (0.3–3.4) 0.9 18 0.7 (0.2–2.4) 0.6
COPD 13 1.6 (0.5–5.7) 0.4 12 1.7 (0.5–6.0) 0.4
Heart failure 12 1.2 (0.3–4.8) 0.7 12 3.7 (1.1–11.9) 0.03
Current or 
previous 
cancer
24 1.3 (0.5–3.4) 0.6 24 2.3 (0.9–5.4) 0.08
Proximal DVTb 161 0.8 (0.4–1.6) 0.6 159 0.9 (0.5–1.8) 0.8
PTS 121 13.9 
(5.7–34.1)
<0.001 11.0 (4.6–29.7) <0.001 120 5.9 (2.9–11.9) <0.001 4.8 (2.3–10.0) <0.001
Multiple DVTs 79 1.4 (0.8–2.7) 0.3 71 1.4 (0.7–2.6) 0.3
Provoked DVT 119 0.8 (0.4–1.5) 0.5 116 1 (0.5–1.7) 0.9
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The study showed that patients reported more prob-
lems in all the five items of EQ-5D compared to buddy-
controls. Of these 5 items pain/discomfort was most 
common complaint in the patient group and was twice 
as prevalent as in the control group. This may be due 
to pain being a symptom of PTS (Kahn et al. 2000). The 
increased prevalence of patients indicating problems in 
the dimensions of mobility and usual activities may also 
be explained by restrictions due to symptoms of PTS. 
Anxiety was also more prevalent among patients. The 
latter is in contradiction to a study by van Korlaar et al. 
(van Korlaar et al. 2004) using SF-36, where no difference 
in mental component scores between DVT patients and 
population norms was found. Several factors may explain 
the reason for increased anxiety among patient, includ-
ing fear of bleeding in those receiving anticoagulation or 
fear of recurrence in those who are not anticoagulated. 
These factors have been shown in other studies to influ-
ence HRQoL many years after a DVT (Casais et al. 2005).
In line with other reports our study confirms the nega-
tive impact of PTS on HRQoL (Kahn et al. 2000). PTS was 
associated with impaired HRQoL assessed by all ques-
tionnaires. PTS can influence HRQoL in several ways: it 
may limit the patients’ working ability, cause persistent 
pain, have cosmetic effect(s), and/or restrict patients’ 
activity of daily living (Kahn et al. 2000). Since treatment 
options for PTS once established are limited (Kahn et al. 
2014), measures to prevent PTS are of importance in 
DVT patients. Strategies for prevention of PTS include 
ensure optimal anticoagulation, use of elastic compres-
sion stockings and catheter directed thrombolysis (Kahn 
et al.2014). However, the effect of compression stockings 
on the incidence of PTS is uncertain (Kahn et  al. 2007) 
and catheter directed thrombolysis and other interven-
tional treatment is not currently recommended for rou-
tine use for the purpose of PTS prevention in the general 
DVT patient population (Kahn et al.2014).
Parallel with other studies we found obesity to be asso-
ciated with impaired HRQoL assessed by EQ-5D (Han 
et  al. 2009). Obesity is known to affect physical activity 
and bodily pain and have a significant negative impact 
on the physical wellbeing (Han et  al. 2009). We also 
found that obesity was associated with impaired HRQoL 
assessed by both VEINES subscales. In our study, how-
ever, obesity was an independent predictor of impaired 
HRQoL. It is conceivable that excess body weight might 
increase venous pressure and promote valvular reflux in 
already compromised veins, impairing HRQoL scores 
measured by VEINES QOL/Sym. The role of weight 
reduction in the management of obese DVT patients 
should be evaluated.
In line with previous studies, we found that unem-
ployment was associated with poorer HRQoL assessed 
by EQ-5D (Garcia-Gordillo MA, Adsuar JC, Olivares 
Table 5 Crude- and adjusted odds ratios (OR) for impaired HRQoL assessed by VEINES-QOL
DVT deep vein thrombosis, ECS elastic compression stockings, BMI body mass index, PTS post thrombotic syndrome, COPD chronic pulmonary obstructive disease, 
Impaired HRQoL VEINES-QOL <25th percentile in patient group (41.7)
# Wald test
a Adjusted for all other significant variables in the multivariate model
b In or above popliteal vein
Variable VEINES-QOL
N = 195 Crude OR (95 % CI) p value# Adjusted ORa (95 % CI) p value# adjusted
Female 67 2.0 (1.1–3.8) 0.025 2.5 (1.1–6.0) 0.04
Age (continuous variable) 195 1.0 (1.0–1.0) 1.0
Time from DVT to examination (continuous variable) 195 1.0 (0.9‑1.2) 0.8
Unemployed 108 1.8 (1.0–3.4) 0.07
BMI > 30.0 kg/m2 56 5.0 (2.6–9.7) <0.001 4.1 (1.7–9.7) <0.001
Current or previous daily smoking 103 1.0 (0.5–1.7) 0.8
Still on anticoagulation 52 1.4 (0.7– 2.7) 0.3
No ECS after DVT 14 0.5 (0.1–2) 0.4
COPD 8 1.2 (0.3–5.4) 0.8
Heart failure 10 9.2 (1.9–44.8) 0.06
Current or previous cancer 13 0.9 (0.3–3.1) 0.9
Proximal DVTb 120 0.8 (0.5–1.7) 0.7
PTS 91 28.7 (11.3–73.0) <0.001 28.2 (10.6–75.0) <0.001
Multiple DVTs 59 1.8 (1.0–3.5) 0.06
Provoked DVT 64 1.1 (0.6–2.1) 0.7
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PR. Normative values of EQ-5D-5L: in a Spanish repre-
sentative population sample from Spanish Health Sur-
vey 2011). In the disease-specific VEINES-QOL/Sym 
employment status was not associated with impaired 
HRQoL. This seems logical as the disease-specific tool 
captures different aspects of HRQoL from the generic 
questionnaire. There was a trend towards female gender 
being a predictor of impaired HRQoL assessed by both 
EQ-5D index value and VEINES-QOL; however, it failed 
to remain significant when controlling for other factors 
(Tables 4, 5).
The association between recurrent DVT and HRQoL 
reported in the literature is inconsistent (Prandoni et al. 
1996; Kahn et  al. 2008). In this study we did not find 
any association between recurrent DVT and reduced 
HRQoL. In most previous reports, proximal DVT was 
found as a predictor of impaired disease specific HRQoL 
(Kahn et  al. 2005, 2008; Rabinovich and Kahn 2014). 
However, in line with Roberts et al. (2014) we did not find 
an association between proximal extension of DVT and 
impaired HRQoL. In contrast with other studies (Kahn 
et al. 2004, 2008) we found that the presence of comor-
bidities (heart failure and COPD) were not associated 
with impaired HRQoL, when adjusting for other factors, 
probably because very few patients had these comorbidi-
ties in our study sample leading to low power.
Interpretation of clinically relevant differences in 
scores is an important issue in HRQoL measurements. 
Nonetheless, there is no definitive consensus on the most 
appropriate method for assessing meaningful differences. 
In this study, we followed criteria established and com-
pared to other measures of health (SF-36) in previous 
investigations of MIDs for EQ-5D-3L (Walters and Bra-
zier 2005; Pickard et  al. 2007), although other methods 
have been reported and used in other studies (Jansson 
et al. 2009).
The major strength of our study is recruitment of unse-
lected DVT patients and the inclusion of buddy controls. 
Although many patients lacked a buddy control, the age 
and sex distribution of patients with buddy controls and 
those without were the same. Comparison with the con-
trol group therefore seems to reflect a real difference in 
HRQoL between patients with and with out a history of 
DVT. The main limitations of this study are that patients 
were identified retrospectively and only 61  % surviving 
patients participated in the study. We therefore cannot 
rule out the possibility of recruiting more patients with 
PTS or other complaints. However, since the prevalence 
and distribution of PTS, comorbidities and localization 
of DVT was comparable to that reported in other studies, 
we consider the risk of such bias as low (Kahn et al.  2014; 
Kahn 2006).
Conclusions
We conclude that DVT patients participating in our study 
had impaired long-term HRQoL as compared with buddy 
controls and population norms. PTS and obesity were the 
most important predictors for impaired HRQoL as meas-
ured by both generic- and disease-specific tools. PTS and 
obesity are modifiable factors; our findings thus emphasize 
the importance of measures to prevent PTS and obesity.
Abbreviations
COPD: chronic obstructive pulmonary disease; CVDL: chronic venous diseases 
of the leg; DVT: deep vein thrombosis; ECS: elastic compression stockings; 
EQ‑VAS: EQ Visual Analogue Scale; EQ‑5D: descriptive system of health‑related 
quality of life states consisting of five dimensions; HRQoL: health related qual‑
ity of life; IQR: interquartile range; MID: minimal clinical important difference; 
PROMs: patient reported outcome forms; PTS: post thrombotic syndrome; 
Obesity: body mass index >30/m2; SD: standard deviation; TTO: time‑trade‑off; 
VEINES‑QOL/Sym: disease‑specific quality of life instrument for use in venous 
diseases of the leg.
Authors’ contributions
KKU, WG, MT, HSW, and PMS were responsible for study concept and design. 
KKU and HSW were responsible for patient recruitment, examination and data 
acquisition. KKU, MT, RH and LPJJ performed the statistical analyses. KKU wrote 
the first draft of the manuscript. All authors were responsible for critical revi‑
sion of the manuscript, interpretation of the results, had full access to all the 
data in the study, and take responsibility of the integrity of the data and the 
accuracy of data analysis. All authors read and approved the final manuscript.
Author details
1 Department of Medicine, Østfold Hospital Trust, Kalnes, Norway. 2 Insti‑
tute of Clinical Medicine, University of Oslo, Oslo, Norway. 3 Department 
of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. 4 Depart‑
ment of Haematology, Oslo University Hospital Rikshospitalet, Oslo, Norway. 
5 Department of Health Science, Østfold University College, Fredrikstad, 
Norway. 6 Institute of Regional Health Research, University of Southern Den‑
mark, Odense, Denmark. 7 Department of Haematology, Østfold Hospital Trust, 
Postbox 300, 1714 Grålum, Norway. 
Competing interests
The authors state that they have no conflict of interest, except Dr. Ghanima 
and Dr. Jelsness‑Jørgensen. Dr. Ghanima reports grants and lecture honoraria 
from Bayer, Novartis and Roche and lecture honoraria from Pfizer and from 
Boehringer Ingelheim—none of which is relevant for the submitted work. 
Dr. Jelsness‑Jørgensen reports unrestricted grants from Ferring pharmaceu‑
ticals and Tillots pharma, and personal fees from Abbvie, not relevant for the 
submitted work.
Availability of data and materials
The complete dataset is available from the first author, upon request.
Ethics approval and consent to participate
The study was conducted according to the principles founded in the revised 
declaration of Helsinki and written informed consent was obtained from each 
individual before entering the study. The study was approved by the Regional 
Committee for Medical and Health Research Ethics Norway (approval no 
2011/2557b).
Funding
Ostfold Hospital Trust solely funded the study. The funding body had no role 
in the design of the study and collection, analysis, and interpretation of data 
or in writing the manuscript.
Received: 27 April 2016   Accepted: 29 July 2016
Page 9 of 9Utne et al. SpringerPlus  (2016) 5:1278 
References
Ashrani AA, Heit JA (2009) Incidence and cost burden of post‑thrombotic 
syndrome. J Thromb Thrombolysis 28(4):465–476
Baldwin MJ, Moore HM, Rudarakanchana N, Gohel M, Davies AH (2013) Post‑
thrombotic syndrome: a clinical review. J Thromb Haemost 11(5):795–805
Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53–72
Casais P, Meschengieser SS, Sanchez‑Luceros A, Lazzari MA (2005) Patients’ per‑
ceptions regarding oral anticoagulation therapy and its effect on quality 
of life. Curr Med Res Opin 21(7):1085–1090
Catarinella F, Nieman F, de Wolf M, Wittens C (2014) Short‑term follow‑up of 
Quality‑of‑Life in interventionally treated patients with post‑thrombotic 
syndrome after deep venous occlusion. Phlebology 29(1 suppl):104–111
Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG et al (2007) 
Venous thromboembolism (VTE) in Europe. The number of VTE events 
and associated morbidity and mortality. Thromb Haemost 98(4):756–764
Enden T, Sandvik L, Klow NE, Hafsahl G, Holme PA, Holmen LO et al (2007) 
Catheter‑directed Venous Thrombolysis in acute iliofemoral vein 
thrombosis–the CaVenT study: rationale and design of a multicenter, 
randomized, controlled, clinical trial (NCT00251771). Am Heart J 
154(5):808–814
EuroQol G (1990) EuroQol–a new facility for the measurement of health‑
related quality of life. Health Policy 16(3):199–208
Garcia‑Gordillo MA, Adsuar JC, Olivares PR. Normative values of EQ‑5D‑5L: in a 
Spanish representative population sample from Spanish Health Survey, 
2011. Qual Life Res. 2015: 1–9
Ghanima W, Kleven IW, Enden T, Rosales A, Wik HS, Pederstad L et al (2011) 
Recurrent venous thrombosis, post‑thrombotic syndrome and quality 
of life after catheter‑directed thrombolysis in severe proximal deep vein 
thrombosis. J Thromb Haemost 9(6):1261–1263
Han JH, Park HS, Shin CI, Chang HM, Yun KE, Cho SH et al (2009) Metabolic 
syndrome and quality of life (QOL) using generalised and obesity‑specific 
QOL scales. Int J Clin Pract 63(5):735–741
Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism 
after deep vein thrombosis: incidence and risk factors. Arch Intern Med 
160(6):769–774
Jansson KA, Nemeth G, Granath F, Jonsson B, Blomqvist P (2009) Health‑related 
quality of life (EQ‑5D) before and one year after surgery for lumbar spinal 
stenosis. J Bone Jt Surg (British Volume) 91(2):210–216
Kahn SR (2006) The post‑thrombotic syndrome: progress and pitfalls. Br J 
Haematol 134(4):357–365
Kahn SR, Solymoss S, Lamping DL, Abenhaim L (2000) Long‑term outcomes 
after deep vein thrombosis: postphlebitic syndrome and quality of life. J 
Gen Intern Med 15(6):425–429
Kahn SR, M’Lan CE, Lamping DL, Kurz X, Berard A, Abenhaim L et al (2004) The 
influence of venous thromboembolism on quality of life and severity of 
chronic venous disease. J Thromb Haemost 2(12):2146–2151
Kahn SR, Elman EA, Bornais C, Blostein M, Wells PS (2005a) Post‑thrombotic 
syndrome, functional disability and quality of life after upper extremity 
deep venous thrombosis in adults. Thromb Haemost 93(3):499–502
Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A et al (2005b) 
Prospective evaluation of health‑related quality of life in patients with 
deep venous thrombosis. Arch Intern Med 165(10):1173–1178
Kahn SR, Shbaklo H, Shapiro S, Wells PS, Kovacs MJ, Rodger MA et al (2007) 
Effectiveness of compression stockings to prevent the post‑thrombotic 
syndrome (the SOX Trial and Bio‑SOX biomarker substudy): a randomized 
controlled trial. BMC Cardiovasc Disord 7:21
Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ et al (2008) 
Determinants of health‑related quality of life during the 2 years following 
deep vein thrombosis. J Thromb Haemost 6(7):1105–1112
Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C, Subcommittee on 
control of anticoagulation of the, S. et al (2009) Definition of post‑throm‑
botic syndrome of the leg for use in clinical investigations: a recommen‑
dation for standardization. J Thromb Haemost 7(5):879–883
Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA 
et al (2014a) The postthrombotic syndrome: evidence‑based preven‑
tion, diagnosis, and treatment strategies: a scientific statement from the 
American Heart Association. Circulation 130(18):1636–1661
Kahn SR, Shapiro S, Wells PS, Rodger MA, Kovacs MJ, Anderson DR et al (2014b) 
Compression stockings to prevent post‑thrombotic syndrome: a ran‑
domised placebo‑controlled trial. Lancet 383(9920):880–888
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ 
et al (2012) Antithrombotic therapy for vte disease: Antithrombotic 
therapy and prevention of thrombosis, 9th ed: American college of 
chest physicians evidence‑based clinical practice guidelines. Chest 
141(2_suppl):e419S–e494S
Kim U, Wittrup‑Jensen JL, Kjeld M, Pedersen KM. Modelling Danish EuroQol 
(EQ‑5D) Tariffs by applying the time trade‑off method. Health Economics 
Papers. 2008; 4.
Kwon HY, Kim E (2016) Factors contributing to quality of life in COPD patients 
in South Korea. Int J Chron Obstruct Pulmon Dis 11:103–109
Lamping DL, Schroter S, Kurz X, Kahn SR, Abenhaim L (2003) Evaluation of 
outcomes in chronic venous disorders of the leg: development of a 
scientifically rigorous, patient‑reported measure of symptoms and quality 
of life. J Vasc Surg 37(2):410–419
Paller C, Smith T (2014) Strategies addressing quality of life: management of 
patient‑reported outcomes and symptoms (current clinical urology). 
Springer, New York
Pickard AS, Neary MP, Cella D (2007) Estimation of minimally important 
differences in EQ‑5D utility and VAS scores in cancer. Health Qual Life 
Outcomes 5:70
Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al (1996) The 
long‑term clinical course of acute deep venous thrombosis. Ann Intern 
Med 125(1):1–7
Rabinovich A, Kahn SR (2014) How to predict and diagnose postthrombotic 
syndrome. Pol Arch Med Wewn 124(7–8):410–416
Roberts LN, Patel R, Donaldson N, Arya R (2014) Post‑thrombotic syndrome is 
an independent determinant of health‑related quality of life following 
both first proximal and distal deep vein thrombosis. Haematologica 
99(3):e41–e43
Sorensen J, Davidsen M, Gudex C, Pedersen KM, Bronnum‑Hansen H (2009) 
Danish EQ‑5D population norms. Scand J Public Health 37(5):467–474
van Korlaar IM, Vossen CY, Rosendaal FR, Bovill EG, Cushman M, Naud S et al 
(2004) The impact of venous thrombosis on quality of life. Thromb Res 
114(1):11–18
Walters SJ, Brazier JE (2005) Comparison of the minimally important difference 
for two health state utility measures: EQ‑5D and SF‑6D. Qual Life Res 
14(6):1523–1532
